EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

CIDP With and Without Monoclonal Gammopathy of Undetermined Significance ( MGUS ): Comparison of Clinical Phenotype, Diagnostic Features, and Treatment Response

R van Veen iD, A E Baars iD, I N van Doorn iD, M Michael, S R M Bus, M C Broers iD, W L van der Pol, P A Van Doorn, J Drenthen, C Verhamme, J M I Vos iD, I N van Schaik und 5 weitere

Journal of the Peripheral Nervous System · 2026-03 · 31 (1)

DOI: 10.1111/jns.70116 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Journal of the Peripheral Nervous System, online erschienen am 12.03.2026. Verfasst von R van Veen und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Amsterdam UMC Location University of Amsterdam, Amsterdam, the Netherlands. Hauptthemen laut MEDLINE: Monoclonal Gammopathy of Undetermined Significance, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CSL-Behring, Grifols, GBS/CIDP Foundation International.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims Monoclonal gammopathy of undetermined significance (MGUS) occurs in some patients with chronic inflammatory demyelinating polyneuropathy (CIDP), but its impact on clinical phenotype and treatment response remains unclear. We assessed the prevalence of paraproteinemia in CIDP and compared disease features between CIDP patients with and without MGUS.

Methods

We used data from the International CIDP Outcome Study (ICOS), a prospective cohort study. We compared the prevalence and causes of paraproteinemia in CIDP to matched disease controls (axonal polyneuropathy or motor neuron disease) and compared disease features and treatment responses between CIDP patients with and without MGUS. Treatment response, defined as a ≥ 1‐point improvement on the modified Rankin scale, was retrospectively assessed.

Results

IgG paraproteinemia was more common in CIDP than in controls (9%, 17/193 vs. 3%, 6/192; p = 0.03). IgM and IgA paraprotein prevalences did not differ. One CIDP patient had Waldenström macroglobulinemia; others had MGUS. Patients with IgG MGUS less often had an acute clinical presentation (6% vs. 33%; p = 0.02), more often had sensory deficits (94% vs. 67%; p = 0.02), and prolonged distal CMAP duration (64% vs. 31%; p = 0.02), compared to patients without MGUS. First‐line treatment response rates were comparable (80% [IgG MGUS] vs. 67% [no MGUS]; p = 0.39).

Interpretation

IgG MGUS is more prevalent in CIDP than in controls. Presence of IgG MGUS is weakly associated with some CIDP disease features, but not treatment response. These findings indicate that, although IgG MGUS is associated with CIDP, the presence of IgG MGUS does not constitute a distinct subgroup with unique clinical features or treatment implications.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Monoclonal Gammopathy of Undetermined SignificancePolyradiculoneuropathy, Chronic Inflammatory DemyelinatingHumansFemaleMaleAgedPhenotypeMiddle AgedTreatment OutcomeRetrospective StudiesProspective StudiesPrevalenceAged, 80 and over

Stichwörter der Autor:innen

chronic inflammatory demyelinating polyneuropathy (CIDP)clinical phenotypemonoclonal gammopathy of undetermined significance (MGUS)nerve conduction studiesparaproteinemiatreatment response

Autor:innen und Institutionen

  • Department of Neurology, Amsterdam UMC Location University of Amsterdam, Amsterdam, the Netherlands.
  • Amsterdam Neuroscience, Neuroinfection and Inflammation, Amsterdam, the Netherlands.
  • Department of Psychiatry, OLVG Hospital, Amsterdam, the Netherlands.
  • Department of Neurology, Erasmus MC, University Medical Center, Rotterdam, the Netherlands.
  • Department of Neurology, Brain Center Rudolf Magnus, University Medical Center, Utrecht, the Netherlands.
  • Department of Haematology, Cancer Center Amsterdam, Amsterdam UMC Location University of Amsterdam, Amsterdam, the Netherlands.

ORCID-Profile: R van Veen, A E Baars, I N van Doorn, M C Broers, J M I Vos, H S Goedee, B C Jacobs, F Eftimov

Förderung

  • CSL-Behring
  • Grifols
  • GBS/CIDP Foundation International
  • CSL Behring

Zitieren

APA

van Veen, R., Baars, A. E., van Doorn, I. N., Michael, M., Bus, S. R. M., Broers, M. C., van der Pol, W. L., Van Doorn, P. A., Drenthen, J., Verhamme, C., Vos, J. M. I., van Schaik, I. N., Goedee, H. S., Wieske, L., Jacobs, B. C., Eftimov, F., & ICOS Consortium (2026). CIDP With and Without Monoclonal Gammopathy of Undetermined Significance ( MGUS ): Comparison of Clinical Phenotype, Diagnostic Features, and Treatment Response. Journal of the Peripheral Nervous System, 31(1). https://doi.org/10.1111/jns.70116

Vancouver

van Veen R, Baars AE, van Doorn IN, Michael M, Bus SRM, Broers MC, et al. CIDP With and Without Monoclonal Gammopathy of Undetermined Significance ( MGUS ): Comparison of Clinical Phenotype, Diagnostic Features, and Treatment Response. Journal of the Peripheral Nervous System. 2026;31(1). doi:10.1111/jns.70116

BibTeX
@article{vanVeen2026,
  author = {van Veen, R and Baars, A E and van Doorn, I N and Michael, M and Bus, S R M and Broers, M C and van der Pol, W L and Van Doorn, P A and Drenthen, J and Verhamme, C and Vos, J M I and van Schaik, I N and Goedee, H S and Wieske, L and Jacobs, B C and Eftimov, F and ICOS Consortium, ICOS Consortium},
  title = {CIDP With and Without Monoclonal Gammopathy of Undetermined Significance ( MGUS ): Comparison of Clinical Phenotype, Diagnostic Features, and Treatment Response},
  journal = {Journal of the Peripheral Nervous System},
  year = {2026},
  volume = {31},
  number = {1},
  doi = {10.1111/jns.70116}
}
Kostenlos starten →